Want to see DE:GXI full AI Analyst Report?
Top Page
Gerresheimer
(XETRA:GXI)
Select Model
Select Model
Rating:52Neutral
Price Target:
€28.00
▲(6.54% Upside)
Action:Reiterated
Date:07/01/26
Overall score is held back primarily by weakening financial performance (swing to losses, higher leverage, and deeply negative free cash flow). Technicals provide support with price trading above key moving averages, and valuation is mixed due to a negative P/E offset partially by a high dividend yield.
Positive Factors
Recurring revenue from regulated drug packaging
Gerresheimer’s core business sells primary pharmaceutical packaging and drug-delivery systems under long qualification cycles and repeat purchase patterns. Regulatory barriers and customer qualification create durable, recurring revenue streams that sustain volumes and customer stickiness over years.
Negative Factors
Sharp swing to operating losses
A sudden move from multi-year profitability to substantial operating and net losses materially weakens earnings power. It reduces internal funding capacity, pressures margins, and raises execution risk if the drivers (costs, impairments, or one-offs) are structural rather than temporary.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue from regulated drug packaging
Gerresheimer’s core business sells primary pharmaceutical packaging and drug-delivery systems under long qualification cycles and repeat purchase patterns. Regulatory barriers and customer qualification create durable, recurring revenue streams that sustain volumes and customer stickiness over years.
Read all positive factors
Gerresheimer (GXI) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€959.52M
Dividend Yield0.14%
Average Volume (3M)538.00K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth14.00%
EPS Growth-391.94%
CountryDE
Employees13,528
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-9.28
Shares Outstanding34,540,000
10 Day Avg. Volume723,177
30 Day Avg. Volume537,996
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.40
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.00Price Target Upside14.16% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)1.87
Revenue Forecast (FY)€2.36B
Gerresheimer Business Overview & Revenue Model
Company Description
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. ...
How the Company Makes Money
Gerresheimer primarily makes money by manufacturing and selling (1) drug containment/primary packaging products and (2) drug-delivery systems to pharmaceutical and healthcare customers. Revenue is generated through long-term supply arrangements an...
Gerresheimer Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
48
Neutral
Cash Flow
30
Negative
| Breakdown | May 2026 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.32B | 2.04B | 1.99B | 1.82B | 1.50B |
| Gross Profit | 425.25M | 607.76M | 597.31M | 546.81M | 442.23M |
| EBITDA | 312.90M | 405.97M | 403.89M | 340.20M | 293.09M |
| Net Income | -320.32M | 109.72M | 116.13M | 96.12M | 83.79M |
Balance Sheet | |||||
| Total Assets | 4.49B | 3.81B | 3.43B | 3.35B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 176.21M | 213.06M | 122.34M | 124.83M | 133.78M |
| Total Debt | 1.60B | 1.28B | 1.04B | 1.22B | 1.13B |
| Total Liabilities | 3.39B | 2.27B | 1.96B | 2.08B | 1.88B |
| Stockholders Equity | 1.08B | 1.51B | 1.45B | 1.24B | 981.32M |
Cash Flow | |||||
| Free Cash Flow | -98.80M | -129.51M | -33.70M | -16.13M | 8.45M |
| Operating Cash Flow | 209.53M | 240.33M | 294.34M | 221.94M | 212.08M |
| Investing Cash Flow | -661.77M | -345.59M | -307.43M | -256.18M | -197.04M |
| Financing Cash Flow | 452.97M | 168.27M | 40.35M | 44.24M | 8.03M |
Gerresheimer Technical Analysis
Positive
26.28
Price Trends
27.16
Positive
25.34
Positive
24.57
Positive
Market Momentum
-0.09
Negative
53.85
Neutral
56.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GXI, the sentiment is Positive. The current price of 26.28 is below the 20-day moving average (MA) of 27.07, below the 50-day MA of 27.16, and above the 200-day MA of 24.57, indicating a bullish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 53.85 is Neutral, neither overbought nor oversold. The STOCH value of 56.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:GXI.
Gerresheimer Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.76B | 12.06 | 10.62% | 2.35% | 6.37% | 71.55% | |
67 Neutral | €844.75M | 16.88 | 20.26% | 1.65% | 4.42% | 35.68% | |
60 Neutral | €272.29M | -560.00 | -1.37% | 3.05% | ― | ― | |
59 Neutral | €1.62B | 26.71 | 11.05% | 4.66% | 0.35% | 116.73% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €959.52M | -3.02 | -23.57% | 0.15% | 14.00% | -391.94% | |
48 Neutral | €14.58B | 82.65 | 6.28% | 0.42% | 3.29% | 88.34% |
* General Sector Average
DE:GXI
Gerresheimer
27.98
-16.92
-37.68%
DE:DRW3
Draegerwerk AG & Co. KGaA
110.20
43.43
65.05%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
13.33
-4.32
-24.46%
DE:PFV
Pfeiffer Vacuum Technology
162.60
13.67
9.18%
DE:SRT
Sartorius
183.60
21.70
13.41%
DE:SBS
STRATEC Biomedical
21.60
-4.50
-17.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.